Helen Philippou

Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland.

Curve Therapeutics Ltd. operates as a drug-discovery company. It engages on the development of innovative technologies to address undruggable disease-modifying targets, with an in-house focus on cancer. The company was founded in 2019 and is headquartered in London, the United Kingdom.

Leucid Bio Ltd. is a clinical-stage biotechnology company based in London, UK. The British company develops novel, lateral car cell therapies for the treatment of refractory cancers, with a focus on developing next-generation cell therapies for the benefit of individuals with hard-to-treat solid tumors. The company's operations are based at Guys Hospital, enabling them to maintain a patient-centric focus. Leucid's goal is to develop CAR-T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers. Leucid was established to translate 20 years of Kings College research in the CAR-T field and is led by a highly experienced management team, including scientific founder John Maher. Filippo Joseph Petti has been the CEO of the company since 2023.

Quaker Partners Management LP (Quaker Partners Mgmt) is a venture capital subsidiary of Independence Capital Partners Inc founded in 2002 by Ira Mark Lubert and Paul Sherrill Neff. The firm is headquartered in Philadelphia, Pennsylvania.

Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA.

Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom.

Keystone Symposia operates as a catalyst for the advancement of biomedical and life sciences by connecting scientists within and across disciplines at conferences and workshops. The company was founded by C. Fred Fox in 1972 and is headquartered in Silverthorne, CO.

Adorx Therapeutics Ltd. provides biotechnology, health care and therapeutics services. The company is headquartered in Edinburgh, the United Kingdom.

Epsilogen Ltd. engages in the development of immunoglobulin E (IgE) antibodies to treat cancer. The firm offers IGEG platform technology based on combining the power of IgE and Immunoglobulin G (IgG) antibody molecules. The company was founded by Sophia Karagiannis and James Spicer and is headquartered in London, United Kingdom.

Clyde Biosciences Ltd. provides developmental drug testing services. It offers drug screening, toxicity data analysis, direct measurements, and drug induced changes investigation services. Its services include calcium, voltage, contractility, in silico modeling, CiPA studies and bespoke R&D. The company was founded by Margaret Anne Craig, Godfrey Smith, Francis Burton, and Jon Cooper on March 9, 2012 and is headquartered in Glasgow, the United Kingdom.

Topas Therapeutics GmbH engages in pharmaceutical preparations. The company is headquartered in Hamburg, Germany.

Dietary Assessment Ltd. provides quick and easy to use nutrition software that allows users to track, monitor, and analyze nutrient intake. The company is based in Leeds, UK. The software was created and validated by academics and is suitable for research, teaching, and healthcare purposes. The British company's myfood24 software has been tailored to support classroom learning and to develop critical skills and capacity in nutrition and health. It can also be used by healthcare professionals to support the prevention, early intervention, and management of diet-related diseases. The company was founded in 2017 by Janet Cade, and the CEO is Stephen Michael Kerridge.

Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany.

Epidarex Exeed Ltd. is a British biotechnology company that specializes in research and experimental development. The company is based in Edinburgh, UK. The company was founded in 2019 by Elizabeth Ann Roper and Henning Steinhagen, with Henning Steinhagen serving as the CEO since its inception.

Caldan Therapeutics Ltd. provides novel therapeutics targeting free fatty acid. It focuses on developing drugs in order to deliver anti-diabetic effects in multiple tissues and organs. The company was founded by Graeme Milligan and Trond Ulven and is headquartered in Edinburgh, the United Kingdom.

PrescribeWell, Inc. provides an online health management system. It offers health care practitioners, physicians and obesity intervention business. The company was founded by Shahid Shah, Amir Jafri, Mervyn J. Turner, Merv Heller and Susan Schramm-Apple in 2014 and is headquartered in Hatfield, PA.

Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Excel Medical Ventures LLC (Excel Medical Ventures) is a venture capital firm founded in 2004 by Steven R. Gullans. The firm is headquartered in Boston, Massachusetts.

PharmAkea, Inc. develops small molecule drug candidates against protein targets involved in fibro proliferative diseases. It discovers and develops small molecule therapeutics directed at cancer and fibrotic diseases. The company was founded by John Howard Hutchinson, Kevin Holme, and Jilly Evans in 2012 and is headquartered in San Diego, CA.

Preventice Technologies, Inc. develops mobile health and wellness platform solutions. It designs monitoring systems, uses the latest in cloud, analytical, and micro-electronic technology to connect patients to their doctors and healthcare providers. The company was founded in 2007 and is headquartered in Minneapolis, MN.

EnGeneIC Pty Ltd. develops and commercializes novel concepts for the targeted delivery of drugs and other therapeutic molecules used in the treatment of cancer. It offers targeted drug delivery, gene silencing, canine cancers and principal characteristics technology solutions. The company was founded by Jennifer A. MacDiarmid and Himanshu Brahmbhatt in 2001 and is headquartered in Sydney, Australia.

Incanthera Research & Development Ltd. develops drug delivery solutions for solid tumor chemotherapy. It offers cancer therapies, such as ICT01-2588, a vascular disrupting agent and drug delivery platform for lung and prostate cancer; and ICT03-Es5, a bioreductive anticancer agent for lung, liver, and breast cancer. The company was founded by Alan McGowan, Paul Loadman, Laurence Patterson, Andrew John Michael Duley, John Anthony Hadfield, Robert Falconer, and Jason Gill in 2010 and is headquartered in Manchester, the United Kingdom.

Part of SAB Biotherapeutics, Inc., SAB Sciences, Inc. operates as a clinical-stage biopharmaceutical development company. The company is based in Sioux Falls, SD. The company was founded in 2014 by Eddie J. Sullivan, Eddie Hamilton, Christine E. Hamilton. Eddie J. Sullivan has been the CEO since 2014. SAB Sciences was acquired by Big Cypress Acquisition Corp. on October 22, 2021 for $452.48 million.

This technology allows physicians and researchers to explore the eye for a broad spectrum of diseases, which have previously required long-term clinical evaluation and invasive testing for definitive diagnosis. Amydis has a discovery platform and proprietary know-how that positions it as a first mover and leader in developing ocular tracers for human diseases. The American company was founded in 2013 by Stella Sarraf, who has been the CEO since then.

Spinogenix, Inc. provides biotechnology services. It offers therapeutics, neurodegeneration, amyloids, traumatic brain injury and neurorestorative. The company was founded by Stella Sarraf in 2016 and is headquartered in San Diego, CA.

Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021.